



FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY, AND ADULTS WITH ACTIVE PSORIATIC ARTHRITIS




# COMPREHENSIVE SUPPORT FOR YOUR PATIENTS

## Important Safety Information

Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

Please see **Important Safety Information** on page 7 and full **Prescribing Information** enclosed, or visit [CIMZIAhcp.com](https://www.cimziahcp.com).

**Help patients start and stay on CIMZIA® once prescribed**



CIMplicity® offers benefits verification, prior authorization support, and specialty pharmacy management through dedicated case managers. We provide multiple access options to help eligible patients to get started on CIMZIA once prescribed.

**CIMplicity Savings Program\***  
Helps your patients save on their prescription

**CIMplicity Injection Training**  
Provides patients with the training support they need to use the CIMZIA prefilled syringe for their CIMZIA therapy

**CIMplicity Covered†**  
Helps ensure patients are on treatment without delay

**CIMplicity Syringe Disposal**  
Offers free syringe disposal containers to patients, so they can dispose of their CIMZIA syringes safely

**CIMplicity Nurse Navigator‡**  
Is your patient's single point of contact for providing treatment support, answering financial questions, and more

\*Savings Program Eligibility: For eligible commercially insured patients only. View complete eligibility requirements and terms at [CIMZIA.com/cimplicity-program](http://CIMZIA.com/cimplicity-program). The parties reserve the right to amend or end this program at any time without notice.

†CIMplicity Covered Eligibility: Eligible commercial patients whose insurance coverage is delayed or denied may receive treatment with the CIMZIA Prefilled syringe at no cost for up to 2 years or until the patient's coverage is approved, whichever comes first. View complete eligibility requirements and terms at [CIMZIA.com/cimplicity-program](http://CIMZIA.com/cimplicity-program). The parties reserve the right to amend or end this program at any time without notice.

‡The CIMplicity Nurse Navigator Program does not provide medical advice and does not replace the care of the healthcare provider.

The CIMplicity program is provided as a service of UCB and is intended to support the appropriate use of CIMZIA. The CIMplicity program may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.

**Important Safety Information**

Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (e.g., corticosteroids or methotrexate) may be at a greater risk of infection.



**THE CIMPLICITY SAVINGS PROGRAM**

Eligible commercially insured patients\* may pay \$0 for their CIMZIA treatment when they sign up for the CIMplicity Savings Program.

**The enrollment process is simple:**

1. Patients go to **CIMplicitysignup.com/support** to register. There, they will complete an online registration form
2. If eligible, they'll **receive a CIMplicity Savings Card** that they can download or print from the site
3. To use their card, all patients have to do is **read their card's number** to their HCP office, specialty pharmacy, or their insurance provider in order to process their copay
4. When it's time for their next treatment, **CIMplicity will call the patient** to confirm they are still on CIMZIA



**SAVING ON REFILLS IS EASY**

Eligible patients can continue to use the same savings card on every refill.

\*Eligibility: Available to individuals with commercial prescription insurance coverage for CIMZIA®. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.


Please see **Important Safety Information** on page 7 and full **Prescribing Information** enclosed, or visit [CIMZIAhcp.com](http://CIMZIAhcp.com).









If insurance is delayed or denied, eligible, commercially insured, self-administering patients may receive free treatment for up to 2 years or until insurance coverage is approved, whichever comes first.

**Verify your patient's eligibility for CIMZIA and get eligible patients started with CIMplicity Covered\* in just two steps:**

- 1.** Fill out the CIMplicity Covered portion of the CIMplicity enrollment form to enroll them in the Bridge program.
  - 2.** Complete and return the **prior authorization (PA)**.
-  **Patient can start on CIMZIA after Prior Authorization Request form is completed and submitted. A PA outcome is not needed for patient to receive treatment.**

**What happens next:**

-  Verification of benefits and PA requirements are returned
-  Eligible patients can start treatment through CIMplicity® Covered™
-  Patient is invited to speak with a Nurse Navigator
-  Once the Prior Authorization is approved and coverage is obtained, CIMplicity triages CIMZIA to a specialty pharmacy

**With CIMplicity Covered, your patient may receive treatment without delay while insurance coverage is determined.**

\*CIMplicity® Covered™ Eligibility: Eligible patients with a valid prescription for CIMZIA can receive treatment with the CIMZIA Prefilled Syringe at no cost for up to two years or until the patient's coverage is approved, whichever comes first. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program or where otherwise prohibited by law. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. For initial enrollment into the program, the patient must be experiencing a delay in, or have been denied, coverage for CIMZIA by their commercial insurance plan. To maintain eligibility in the program, the following are required: (1) a prior authorization request has been submitted and/or coverage remains unavailable for the patient; and (2) if the prior authorization is denied by the payer, the prescriber must submit an appeal within the first sixty (60) days of the prior authorization denial and a prior authorization must be submitted every six (6) months thereafter or documentation as may otherwise be required by the payer. UCB reserves the right to rescind, revoke, or amend this Program without notice.

**Important Safety Information**



Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers, including children, adolescents, and young adults. Acute and chronic cases of leukemia have also been reported. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including CIMZIA. Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-antagonists, including CIMZIA. Periodic skin examinations are recommended for all patients, particularly those with risk factors for skin cancer.

**PERSONALIZED SUPPORT TO HELP KEEP PATIENTS ON TRACK**

Patients can receive one-on-one support through their dedicated Nurse Navigator,\* gaining access to tools to help themselves stay on track while you work with them on their treatment.

\*The CIMplicity Nurse Navigator Program does not provide medical advice and does not replace the care of the healthcare provider.

**Nurse Navigators can help your patients with:**

-  Treatment journals
-  Injection training and support
-  Financial assistance support
-  Medication reminders
-  Nutrition and wellness training
-  Goal setting

**CIMplicity Nurse Support Communications:**

**WEEK 2**

- Welcome Call and Injection Training
- Welcome Kit and Patient Journal Shipped

**WEEK 4**

- Nutrition, wellness, and goal setting

**WEEK 8**

- Stress management and/or smoking cessation

**WEEK 12**

- Goal overview and patient satisfaction check-up

**WEEK 12 (FOR PATIENTS WITH PSORIASIS)**

- Long-term goals and strategies, and social expectations

**MONTH 6-12**

- Ongoing conversations to identify and address individual patient needs



**GETTING YOUR PATIENTS ENROLLED IN CIMPLICITY NURSE SUPPORT**

Patients can **contact** their Nurse Navigator directly at **1-844-UCB-Nurse** (1-844-822-6877). Spanish-language support is also available at 1-877-294-0280.

Hours: Monday–Friday, 8 AM–8 PM ET

Please see **Important Safety Information** on page 7 and full **Prescribing Information** enclosed, or visit [CIMZIAhcp.com](http://CIMZIAhcp.com).

## PREPARING YOUR PATIENTS FOR INJECTIONS AT HOME

Patients can receive injection training and support resources for self-injection at home.



Your patient or their caregiver will **receive the training they need** at your office to use CIMZIA<sup>®</sup> (certolizumab pegol) prefilled syringe for their CIMZIA therapy



For full injection training, **patients should reference the “Instructions for Use” booklet**, which is available with their CIMZIA prefilled syringe drug kit or on CIMZIA.com



For further assistance, patients may be directed to a **self-injection instructions video at [CIMZIA.com/injection-training](https://www.cimzia.com/injection-training)**



**CIMplicity<sup>®</sup> offers assistance for your patients to keep their treatment on track, including:**

- Free sharps disposal containers
- Medication reminders
- Patient welcome kit
- Patient journal
- And more!

### Important Safety Information

Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus in patients who are chronic carriers of the virus. In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal.

### INDICATIONS

- CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- CIMZIA is indicated for the treatment of adults with active psoriatic arthritis.

### Important Safety Information

#### CONTRAINDICATIONS

CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.

#### SERIOUS INFECTIONS

Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue CIMZIA if a patient develops a serious infection or sepsis.

Reported infections include:

- Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

- Do not start CIMZIA during an active infection, including localized infections.
- Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
- If an infection develops, monitor carefully and initiate appropriate therapy.

#### MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

- Consider the risks and benefits of CIMZIA treatment prior to initiating or continuing therapy in a patient with known malignancy.
- In clinical trials, more cases of malignancies were observed among CIMZIA-treated patients compared to control patients.
- In CIMZIA clinical trials, there was an approximately 2-fold higher rate of lymphoma than expected in the general U.S. population. Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk of lymphoma than the general population.
- Malignancies, some fatal, have been reported among children, adolescents, and young adults being treated with TNF blockers. Approximately half of the cases were lymphoma, while the rest were other types of malignancies, including rare types associated with immunosuppression and malignancies not usually seen in this patient population.
- Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including CIMZIA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis, and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treating with CIMZIA in these patient types.
- Cases of acute and chronic leukemia were reported with TNF blocker use.

#### HEART FAILURE

- Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers. Exercise caution and monitor carefully.

#### HYPERSENSITIVITY

- Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness, and urticaria have been reported following CIMZIA administration. If a serious allergic reaction occurs, stop CIMZIA and institute appropriate therapy. The needle shield inside the removable cap of the CIMZIA prefilled syringe contains a derivative of natural rubber latex which may cause an allergic reaction in individuals sensitive to latex.

#### HEPATITIS B VIRUS REACTIVATION

- Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
- Test patients for HBV infection before initiating treatment with CIMZIA.
- Exercise caution in patients who are carriers of HBV and monitor them before and during CIMZIA treatment.
- Discontinue CIMZIA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatment.

#### NEUROLOGIC REACTIONS

- TNF blockers, including CIMZIA, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, seizure disorder, optic neuritis, peripheral neuropathy, and Guillain-Barré syndrome.

#### HEMATOLOGIC REACTIONS

- Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with CIMZIA.
- Consider stopping CIMZIA if significant hematologic abnormalities occur.

#### DRUG INTERACTIONS

- Do not use CIMZIA in combination with other biological DMARDs.

#### AUTOIMMUNITY

- Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

#### IMMUNIZATIONS

- Patients on CIMZIA should not receive live or live-attenuated vaccines.

#### ADVERSE REACTIONS

- The most common adverse reactions in CIMZIA clinical trials (≥8%) were upper respiratory infections (18%), rash (9%), and urinary tract infections (8%).



FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY, AND ADULTS WITH ACTIVE PSORIATIC ARTHRITIS

# SIMPLIFYING HOW TO GET PATIENTS STARTED

From multiple enrollment options to personalized onboarding support for your patients, CIMplicity® is here to help you get your patients started on treatment as smoothly as possible.

## PATIENTS CAN SIGN UP FOR CIMPLICITY IN 3 EASY STEPS

- 1 Scan QR code with their phone or visit [CIMplicitysignup.com/support](https://CIMplicitysignup.com/support).
- 2 Complete registration form.
- 3 Their Nurse Navigator\* will contact them by phone to welcome them into the program. They can expect a call from **1-844-822-6877**.



Please advise patients to save this number in their contacts as "CIMplicity Nurse Navigator" for their convenience.

\*The CIMplicity Nurse Navigator Program does not provide medical advice and does not replace the care of the healthcare provider.

### Important Safety Information

Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

Please see Important Safety Information on page 7 and full Prescribing Information enclosed, or visit [CIMZIAhcp.com](https://CIMZIAhcp.com).



CIMZIA®, CIMplicity®, cimplicity®, and ucbCARES® are registered trademarks, and CIMplicity® Covered™ is a trademark, of the UCB Group of Companies. All other trademarks are the property of their respective holders. ©2023 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-P-CZ-PSO-2200226. Printed in the USA.

